Epidemiology, Diagnosis and Treatment Outcomes of Skin Melanoma in the Republic of Belarus by A. G. Zhukovets et al.
__________________________________________________________________________________________________ 
 
*Corresponding author: Email: okeanov@nsys.by; 
Co-author author: Email: zhukavets@tut.by; 
 
 
Journal of Cancer and Tumor International 
5(4): 1-13, 2017; Article no.JCTI.33797 
ISSN: 2454-7360 
 
SCIENCEDOMAIN international 
             www.sciencedomain.org 
 
 
Epidemiology, Diagnosis and Treatment Outcomes 
of Skin Melanoma in the Republic of Belarus 
 
A. G. Zhukovets1, A. E. Okeanov2* and P. I. Moiseyev2 
 
1Department of Oncology, Belarusian Medical Academy of Post-Graduate Education, Minsk, Belarus. 
2N.N. Alexandrov National Cancer Centre, Minsk, Belarus. 
   
Authors’ contributions 
  
This work was carried out in collaboration between all authors. Author AGZ designed the study and 
wrote the protocol. Author AEO performed the statistical analysis, analyses of the study and wrote the 
first draft of the manuscript. Author PIM managed the analyses of the study and the literature 
searches. All authors read and approved the final manuscript. 
 
Article Information 
 
DOI: 10.9734/JCTI/2017/33797 
Editor(s): 
(1) Dr. Dragos C. Luca, Department of Pathology, Children’s National Medical Center/George Washington University, USA. 
Reviewers: 
(1) Wenyin Shi, Thomas Jefferson University, USA. 
(2) Alexander N. Orekhov, Institute of General Pathology and Pathophysiology, Russian Academy of Medical 
 Sciences, Russia. 
Complete Peer review History: http://www.sciencedomain.org/review-history/19435 
 
 
 
Received 29th April 2017 
Accepted 1st June 2017 
Published 9th June 2017 
 
 
ABSTRACT 
 
The primary incidence of skin melanoma in the Republic of Belarus over 25 years (from 1991 
through 2015) has increased 3.3-fold (from 2.6 to 9.0 per 100,000 population). A higher level of 
urban population incidence, a large proportion of people affected at the employable age. In 2015 
the proportion of prognostically unfavourable pT3-pT4 neoplasms was 38.2%. Metastatic disease 
was detected in 12.4% of the patients.  
Methodology: Material of the paper is based on the data of Belarusian Cancer Registry using the 
principles of data collection, monitoring and processing recommended by the IARC.  
Results: The proportion of stage IB neoplasms made up almost one third of the cases assigned to 
stage I. Of the cases assigned to stage II, the proportion of neoplasms with a high prognostic index 
of metastatic spread (T3b-T4b) was more than 70%. The recurrence rate is 15.1% even at 
melanoma invasion depth of up to 1 mm (with ulceration), while it rises to 32.4% at pT2b. The 
cumulative 5-year disease-specific survival of all patients in 2005 was 54.1 ± 1.5%, and in 2015 it 
was 64.0±2.2%.  
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Conclusion: A strong correlation is observed between survival of patients and the extent of 
invasion and ulceration of the primary focus. For metastasis-free pT1a melanoma, the 5-year 
survival was 92.2%, for T1b – 79.9%, for pT2b – 72.5%, for pT3b – 55.1%, for pT4b – 49.1%. 
According to the Cancer Registry data, ulceration of the primary neoplasm is frequently observed: it 
amounts to 41.1% of the cases with melanoma invasion depth up to 2 mm (pT2), to 55.9% with 2-4 
mm (pT3) and to 76.3% with the tumor thickness of more than 4 mm (pT4). 
 
 
Keywords: Skin melanoma; incidence; diagnosis; survival. 
 
1. INTRODUCTION 
 
The medical and social significance of skin 
melanoma (ICD-10:C43) is determined by its 
incidence growth, high potential of malignancy, 
early metastatic disease, frequent recurrence 
after treatment, and a high proportion of patients 
in the employable age. 
 
In the European region, the standardized rates of 
skin melanoma incidence vary quite widely – 
from 4.0 to 20.3 per 100,000 population 
(standardized World values, WHO, GLOBOCAN 
2012) [1]. The highest melanoma incidence rates 
are in Switzerland, the Netherlands, Denmark, 
Sweden, Great Britain. This value is 3-4-fold 
lower in Poland, Lithuania, Latvia, Ukraine, and 
Russia. The situation on the other continents is 
greatly variable but is also not related directly to 
insolation. Evident ethnic differences can be 
traced. India and Japan, countries with a rather 
high insolation level but predominantly aboriginal 
population, have a low melanoma incidence (0.2 
- 0.6 per 100,000 population). Israel and the US, 
countries with a high percentage of fair-skin 
migrants and strong ultraviolet radiation, register 
quite high incidence levels (11.4-14.3 per 
100,000 population), but they are significantly 
lower than in the Netherlands and Denmark. The 
highest incidence was noted in Australia (34.9 
per 100,000) [1]. The most significant risk factors 
of skin melanoma development are excess 
ultraviolet radiation associated with genetic 
predisposition (fair skin susceptible to sunburns 
with numerous melanocyte nevi, familial atypical 
nevi syndrome [FAMM syndrome], germ-line 
mutations in cell cycle regulation genes CDKN2A 
and CDK4, and also in other genes) [2-6]. 
 
A Swedish study [4] based on the Cancer 
Registry data found a statistically significant 
association of skin melanoma incidence with 
office work. It was most evident on clothes-
covered body areas while no difference was 
observed on uncovered ones. The standardized 
hazard ratio was 1.08 (95% CI:1.02-1.15). 
 
The skin melanoma incidence risk is significantly 
increased in younger people tanning in solaria.     
A meta-analysis of 10 studies [7] found an 
increased relative risk of skin melanoma 
associated with solarium tanning (from 1.25 
[95%CI: 1.05-1.49] to 1.69 [95%CI: 1.32-2.18] 
compared to those never practicing artificial 
tanning. 
 
The objective of this study is an analysis of the 
basic epidemiological patterns of skin melanoma 
prevalence in the Republic of Belarus, the rates 
and terms of the disease progression, and 
cumulative cause-specific survival. 
 
2. MATERIALS AND METHODS 
 
The material of the paper is based on the data of 
Belarusian Cancer Registry which is the most 
comprehensive information resource of newly 
and previously registered cases of malignant 
neoplasms within the confines of this country, 
using the principles of data collection, monitoring 
and processing recommended by the IARC. The 
analysis of skin melanoma incidence data 
according to ICD-10 C43.0-C43.9 codes was 
made for the period of 1991-2015. To compare 
the incidence by sex and residence, 
standardized World values per 100,000 
population were used. To compare skin 
melanoma incidence and mortality in certain 
countries of the world, the GLOBOCAN 2012 
electronic resource was used. The values of 
cumulative disease-specific survival presented in 
this paper were actuarially calculated using 
standard techniques and were derived from the 
data on the newly diagnosed cases in 2000-2004 
(by the end of 2005) and 2010-2014 (by the end 
2015). In the cases of malignant second 
primaries occurring with skin melanoma, only 
melanoma-related deaths were taken into 
account. The deaths from other causes including 
other malignancies were allowed for as 
censored. The TNM distribution of the diseases 
was made in accordance with the 7th edition of 
the TNM classification. 
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3. RESULTS AND DISCUSSION 
 
In 2015 skin melanoma accounted for 1.7% 
(1.4% in males, 2.1% in females) in the incidence 
distribution of all malignant neoplasms, including 
leukemia, in the Republic of Belarus. 
 
The most common site affected by melanoma 
was the skin of the trunk and upper and lower 
extremities which in total amounted to 81.1% of 
all registered cases in 2011-2015 (Table 1), with 
preferential melanoma involvement of clothes-
covered body areas. 
 
The comparison of the two 5-year periods shows 
that skin melanoma of the trunk and upper 
extremities, including the shoulder girdle, tended 
to occur more commonly (by 15%), while the 
lower extremities were affected less commonly 
by (14%). This tendency is observed in both men 
and women, with male tumor sites on the trunk 
skin accounting for 52.9% over the past 5 years. 
In women, the incidence rate of lower extremity 
melanoma decreased from 47.7% to 33%, still 
being the most common tumor site. 
 
The analysis of crude values demonstrates a 
significant growth of new cases of the disease. 
Over the 25 years (1991-2015), the primary 
incidence rose 3.3-fold (from 2.6 to 9.0 per 
100,000 population), owing to both female (from 
3.1 to 10.2) and male (from 2.3 to 7.6) incidence 
growth (Fig. 1). 
 
The standardized values also corroborated this 
incidence growth but their growth rates were 
almost 2 times lower than those of the crude 
ones (regression ratios 0.142 and 0.258, 
respectively), suggesting an approximately equal 
contribution of the changes in the age distribution 
of the population, including the gain in lifespan 
and the impact of other etiological factors, to the 
incidence rates rise (Figs. 1 and 2). 
 
One of the distinctive features of skin melanoma 
incidence trends in this country is its more rapid 
growth among the urban residents (Fig. 3). The 
urban dwellers are 1.5-fold more likely to be 
affected by melanoma, which may be partially 
determined by their longer lifespan and, 
seemingly, by frequent sporadic tanning. 
 
In the Republic of Belarus, just as in many other 
world regions, skin melanoma incidence in 
women is higher than that in men. At the same 
time, male incidence is higher in a number of 
neighbouring countries such as Lithuania and 
Poland. A similar tendency is noted in the USA, 
Canada, Slovakia, Israel and Finland1. However, 
statistically significant differences in incidence by 
sex are observed only among rural residents of 
this country, with no phenomenon of this kind 
among townsfolk (Fig. 3). 
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Fig. 1. The trends in crude values of skin melanoma incidence per 100,000 male and female 
population of the Republic of Belarus, 1991-2015 
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Table 1. The number of registered cases and skin melanoma incidence distribution in the Republic of Belarus, 1991-1995 and 2011-2015 
 
 Site 1991-1995 2011-2015 
Males Females Both sexes Males Females Both sexes 
N % N % N % N % N % N % 
C430 Lip 0 0 2 0,2 2 0,1 1 0,1 4 0,2 5 0,1 
C431 Eyelid, including palpebral commissure 6 1,1 8 0,8 14 0,9 4 0,3 13 0,6 17 0,4 
C432 Ear, and external acoustic meatus 11 2,1 16 1,6 27 1,8 16 1,1 47 2,0 63 1,7 
C433 Other facial parts 41 7,7 111 11,4 152 10,1 108 7,3 252 10,8 360 9,5 
C434 Hairy portion of head and neck 45 8,4 26 2,7 71 4,7 101 6,9 56 2,4 157 4,1 
C435 Trunk 218 40,8 198 20,3 416 27,6 778 52,9 658 28,2 1436 37,8 
C436 Upper extremity including the shoulder joint area 84 15,7 121 12,4 205 13,6 231 15,7 466 20,0 697 18,3 
C437 Lower extremity including the hip joint area 117 21,9 464 47,7 581 38,6 178 12,1 770 33,0 948 24,9 
C438 Spreading beyond one site 6 1,1 14 1,4 20 1,3 16 1,1 14 0,6 30 0,8 
C439 Not otherwise specified (NOS) 6 1,1 13 1,3 19 1,3 38 2,6 51 2,2 89 2,3 
 Total: 534 100 973 100 1507 100 1471 100 2331 100 3802 100 
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Fig. 2. The trends in standardized world values of skin melanoma incidence per 100,000 male 
and female population of the Republic of Belarus, 1991-2015 
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Fig. 3. Mean 5-year levels (2011-2015) of skin melanoma incidence in the population of the 
Republic of Belarus, depending on sex and residence (standardized world values per 100,000 
population and 95% confidence intervals) 
 
The highest level and the largest incidence 
increase were in the southern Gomel region (Fig. 
4). Generally, the incidence level in the whole 
population of Gomel region does not statistically 
differ from the mean national level, nor from the 
level of Vitebsk region, the farthest northern one. 
However, these differences are prominent in the 
analysis of urban population incidence (Fig. 5). 
 
The incidence among the urban residents of 
Gomel region proved to be the highest in the 
country, while it was statistically significantly 
lower than in most other regions among the 
villagers. It should be noted that this region was 
most of all radionuclide-contaminated as the 
result of the Chernobyl accident. 
 
Nevertheless, no relation to melanoma incidence 
is found, although rural residents are at the 
highest risk of direct skin contact with long-lived 
isotopes. So the incidence among the villagers of 
Gomel region is statistically significantly lower 
than in Vitebsk region virtually unpolluted with 
long-lived isotopes. 
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Fig. 4. Mean 5-year levels of skin melanoma incidence in the population of the Republic of 
Belarus (standardized world values per 100,000 population and 95% confidence intervals, 
1991-1995 and 2011-2015) 
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Fig. 5. Mean 5-year levels of skin melanoma incidence in the urban and rural population of the 
Republic of Belarus (standardized world values per 100,000 population and 95% confidence 
intervals), 2011-2015 
 
Skin melanoma incidence rates grow with age, 
the increase beginning from the age of 20      
(Fig. 6). Compared with 1991-1995 period, the 
incidence peak shifted from the 70-74 age group 
to 80-84. The bulk of the growth was in the age 
group of people older than 50. The incidence 
levels among younger persons increased to a 
lesser extent vs the initial period. Variances in 
incidence age distribution are observed between 
the male and female population: the incidence 
rates in women under 60 are higher than in men, 
while they are considerably lower in older age 
groups (Fig. 7). Thus, a higher-female incidence 
as a whole is determined by higher incidence 
rates in women of young and middle age. A 
similar age distribution is noted in urban 
residents, their incidence rates being higher. The 
incidence among rural women exceeds that of 
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rural men in all age groups, and the incidence 
levels in the villagers older than 50 are 1.5-3-fold 
lower than in the townsfolk. 
 
In general, the proportion of melanoma cases in 
the employable population was 42.1% in 2015: 
48.8% were male cases and 37.7% were female, 
which is mainly due to earlier retirement age of 
women. 
Early diagnosis of skin melanoma is still a 
pressing issue. The state of things has 
somewhat improved over the past 10 years. The 
share of patients with neoplasms diagnosed in 
stage I has increased while the proportion of 
stage III and IV patients has decreased (Fig. 8). 
At the same time, the conventional four-stage 
presentation of the information is far from the 
complete perception of the problem status. 
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Fig. 6. Age values of skin melanoma incidence in the population of the Republic of Belarus 
(mean values per 100,000 population of the relevant age, 1991-1995, 2001-2005 and 
2011-2015) 
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Fig. 7. Age values of skin melanoma incidence in the male and female population of the 
Republic of Belarus (mean values per 100,000 population of the relevant age and sex, 2011-
2015) 
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It is well known that the potential of the supposed 
melanoma progression is associated with the 
tumor depth and its ulceration. A more detailed 
characterization of newly diagnosed skin 
melanoma cases entered in the cancer registry in 
2015 is shown in Tables 2 and 3. 
 
Summing up the data of Table 3, it is worth 
noting that the proportion of pT4b tumors with 
poor prognosis amounted to 38.2% of cases 
diagnosed in II stage. Metastatic disease stages 
were found in 12.4% of the of all newly 
diagnosed cases, including distant metastases          
in 4.7%. The share of metastatic melanoma 
stages (regional and distant metastases) with 
pT1-pT2 primary tumor was 3.2% with pT3-pT4 - 
17.4%. Of 32 patients with primary tumors 
impossible to be assessed (TX), 18 cases                   
had distant metastases and 3 had regional ones 
(N3). Stage IB neoplasms accounted for                 
almost one third of the cases assigned to      
stage I. 
Of all the cases assigned to stage II, the 
proportion of tumors with high prognostic index of 
metastatic disease (stages IIB and IIC, T3b-T4b) 
was more than 70%. 
 
Of 4258 patients taken ill with skin melanoma in 
2010-2015, 88.9% received curative treatment. 
During that time period, of all the patients 
subjected to curative treatment, there were 1625 
(39.7%) cases of disease progression, including 
regional and distant metastases requiring repeat 
management. 
 
The overwhelming majority of relapses and 
metastases (72.7%) developed in the course of 
less than 3 years after treatment completion. 
Melanoma progression occurred 5 years later in 
15% of the cases. 
 
Of certain interest is the distribution of patients 
with non-metastatic stage of skin melanoma by 
the disease progression rates after curative 
treatment, with regard to the pT category. 
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Fig. 8. Stage distribution of newly diagnosed skin melanoma cases 
 
Table 2. Distribution of newly diagnosed skin melanoma cases in 2015 according to TNM 
 
T N (M0) M Total 
 0 1 2 3 x 1 x  
1 93 0 1 0 1 1 0 96 
1a 157 0 0 1 0 2 1 161 
1b 14 0 2 0 0 0 0 16 
2a 93 1 1 0 2 3 0 100 
2b 30 1 0 0 0 0 0 31 
3а 74 0 4 2 2 3 1 86 
3b 61 3 0 3 0 1 1 69 
4а 50 5 3 2 0 6 1 67 
4b 133 17 5 10 3 5 1 174 
x 7 0 0 3 1 18 3 32 
Total 712 27 16 21 9 39 8 832 
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Table 3. pTNM stage distribution of skin melanoma cases newly diagnosed in 2015 
 
Stage TNM Number % of total %  of stage subtotal 
I Т1N0M0 93 11,2 26,0 
IА Т1аN0M0  157 18,9 44,0 
IВ Т1в-T2aN0M0 107 12,9 30,0 
I (subtotal)  357 43,0 100,0 
IIА Т2в -T3aN0M0 104 12,5 29,9 
IIВ T3b-T4a N0M0 111 13,3 31,9 
IIС Т4bN0M0 133 16,0 38,2 
II (subtotal)  348 41,8 100,0 
III T1-4N1-3M0 64 7,7 100,0 
IV T1-4N1-3M1 39 4,7 100,0 
unspecified  24 2,8 100,0 
Total  832 100,0  
 
The data presented in Fig. 9 and Table 4 
demonstrate that the progressing frequency of 
disease is highly dependent on tumor depth and 
ulceration presence. 
 
A low risk of melanoma progression after 
curative treatment is noted only with pT1a. With 
tumor depth up to 1mm but having ulceration, the 
recurrence rate is already 15.1%, and with pT2b 
and pT3b it grows up to 32.4% and 51.1%, 
respectively (2-4 times higher). 
 
The relapses detected in the course of the first 
year after curative treatment of melanoma 
suggest that the primary tumor was of a more 
advanced character which is not always 
manageable to be assessed using routine 
examination techniques. 
 
This is also supported by the fact that of 256 skin 
melanoma-related deaths in 2015, more than a 
half of the cases had early stages of the disease 
(stage I – 18.4%, stage II – 54.9%). 
The survival of patients with skin melanoma is an 
integral checkup index of diagnosis, treatment 
and surveillance efficacy. The cumulative 5- year 
disease- specific survival of all patients  all 
stages, irrespective of treatment newly 
diagnosed in 2000-2004 (by the end of 2005) 
was 54.1±1.5%., in 2010-2014 (by the end of 
2015) – 64.0±2.2%. 
 
Over the 10–year period, the 5-year survival 
considerably increased only in stage I patients 
(from 74.9±2.7% to 87.4±1.6%), with no 
statistically significant changes in survival with 
stage II and IV, and decreased survival in stage 
III patients (from 42.8±2.6% to 31.5± 3.8%). 
 
Significant sex-dependent differences in survival 
are noticeable: The survival rates in the female 
cohort are considerably and statistically 
significantly higher than those in men (69.9% and 
51.4%, respectively). A similar relationship is 
also observed in gender-dependent survivals 
compared for the (2005-2009) time period with 
calculating the values for 2010. 
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Fig. 9. Progressing frequency with non-metastatic stage of skin melanoma curative treatment 
completion (2010-2015) 
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A strong association is observed between 5-year 
cumulative disease-specific survival of patients 
with non-metastatic stages and tumor depth and 
ulceration presence in the primary focus, 
demonstrating the aggressive potential of 
melanoma. 
 
The 3-year survival rates of pT1b-pT2a 
melanoma patients are 96-98%, their 5-year 
rates being 80-83%, i.e. the disease recurs 
mainly in the time period exceeding 3 years.     
With primary pT2b-pT4b disease, the survival 
rates deteriorate just in the first follow-up year 
(Table 5). 
 
The analysis of primary melanoma ulceration 
incidence found a definite relation with its depth 
with tumor depth of 2 mm (pT2), ulceration of the 
primary tumor focus occurs in 41.1% of the 
cases, with tumor depth of 2 to 4 mm (pT3) in 
55.9%, and with a depth of more than 4 mm. 
(pT4) in 76.3%. 
 
Table 6 presents the cumulative rates of disease-
specific survival of skin melanoma patients 
receiving curative treatment, with regard to tumor 
stage. One-year survival and mortality/incidence 
ratio are among the most important indices 
characterizing the quality of specialized medical 
care provision and melanoma diagnosis. 
 
The values of incidence, mortality and 
mortality/incidence ratio for skin melanoma are at 
great variance in different countries (Table 7). 
Unfortunately, it should be stated that the 
Republic of Belarus is not among the countries 
with low mortality/incidence ratios. In 2012 the 
mortality/incidence ratio for melanoma was 
32.6%, in 2015 - 28.1%, suggesting of 
considerable reserves on organization of early 
detection and treatment of skin melanoma. Over 
the recent decade, the vector of the trend for this 
index changed, although it is less prominent and 
associated with improvements in treatment rather 
than in diagnosis. 
Table 4. Curative treatment coverage and disease progression rates in patients with non-
metastatic stage of skin melanoma, depending on its pT extension, 2010-2015 
 
pT Number 
of newly 
diagnose
d cases 
Completed 
radical treatment 
Disease 
progression 
Of them, in the course of (%) 
Number % Number % Less 
than 1 
year 
1-2 
years 
3-4 
years 
5 years 
and 
more 
рТ1а 565 556 98,4 36 6,5 33,3 36,1 30,6 0 
рТ1в 87 86 98,9 13 15,1 46,2 38,5 15,4 0 
рТ2а 267 261 97,8 51 19,5 13,7 62,7 23,5 0 
рТ2b 174 173 99,4 56 32,4 39,3 51,8 8,9 0 
рТ3а 232 229 98,7 84 36,7 42,9 46,4 9,5 1,2 
рТ3b 286 282 98,6 144 51,1 43,1 46,5 9,7 0,7 
рТ4а 155 154 99,4 87 56,5 50,6 41,4 8,0 0 
рТ4b 538 523 97,2 313 59,8 54,6 39,6 5,1 0,6 
Total 2304 2264 98,3 784 34,6 45,9 44,0 9,6 0,5 
 
Table 5. Cumulative disease-specific survival of patients with non-metastatic stages of skin 
melanoma, depending on the extent of primary tumor spread (pT) (all newly-diagnosed 
patients in 2010-2014 with calculating the values for 2015) 
 
 Probability to survive up to the end of the follow-up period, % 
 1st year SE 2nd year SE 3rd  year SE 4th year SE 5th year SE 
рТ1а 100 0 99,4 0,4 98,1 0,9 95,1 1,7 92,2 2,6 
рТ1b 100 0 98,4 1,6 88,6 4,9 79,7 7,4 79,7 7,4 
рТ2а 100 0 95,9 1,5 90,9 2,5 85,7 3,4 83,2 4,1 
рТ2b 98,6 1,0 95 2,0 79,9 4,5 77,5 5 72,5 6,7 
рТ3а 98,9 0,8 92,9 2,1 82,6 3,4 81,4 3,5 72,9 5,1 
рТ3b 95,8 1,4 85,4 2,6 75,2 3,6 64,3 4,7 55,1 5,9 
рТ4а 97,5 1,4 87,8 3,3 80,1 4,5 65,1 6,3 61,4 6,9 
рТ4b 91,4 1,4 74,4 2,4 60,9 3 53,2 3,5 49,1 3,9 
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Table 6. Cumulative disease-specific survival of skin melanoma patients receiving curative treatment, with regard to tumor stage (treated in 2010-
2014 with calculating the values for 2015) 
 
Stage* Number of 
patients at the 
start of the 
follow-up period 
Died of malignant 
neoplasms during 
the follow-up period  
Died of other diseases 
during the 
follow-up period 
Quitted the 
follow-up, their 
lot unknown 
Number of 
patients at the end 
of the follow-up 
period  
Cumulative 
survival rate 
Cumulative 
rate error 
I 823 38 24 139 662 90,2 1,7 
IA 410 11 6 75 318 92 2,7 
IB 290 27 10 37 216 81,3 3,8 
IIA 291 27 10 38 216 81,4 3,8 
IIB 347 74 31 54 188 57,7 4,5 
IIC 396 123 34 54 185 50,0 4,0 
IIIB 66 29 6 3 28 35,1 10,2 
IIIC 91 53 8 6 24 25,4 5,9 
IV 37 19 2 4 12 33,6 10,7 
*No data on stage IIIA as the number of patients was insufficient for calculating cumulative disease-specific survival
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Table 7. Incidence, mortality and mortality/incidence ratios (%) (GLOBOCAN 2012) [1] 
 
Countries  Incidence Mortality Mortality/incidence 
ratio% 
Male Female Both 
sexes 
Male Female Both 
sexes 
Both sexes 
Belarus* 3,6 4,6 4,1 1,8 1,6 1,7 41,5 
Belarus** 4,0 4,7 4,3 1,7 1,3 1,4 32,6 
Great Britain 13,7 15,6 14,6 2,2 1,5 1,8 12,3 
Germany 11,1 12,0 11,4 1,7 1,1 1,4 12,3 
Denmark 16,6 22,1 19,2 2,5 1,8 2,1 10,9 
Latvia 5,4 6,0 5,6 2,2 2,0 2,0 35,7 
Lithuania 5,4 5,1 5,2 2,5 1,3 1,8 34,6 
Netherlands 17,2 21,8 19,4 3,2 2,5 2,8 14,4 
Poland 4,3 3,9 4,1 2,5 1,6 2,0 48,8 
Russian 
Federation 
3,7 4,4 4,1 1,9 1,4 1,6 39,0 
Slovakia 10,9 9,2 9,9 2,6 1,7 2,1 21,2 
Ukraine 3,7 4,4 4,0 1,9 1,4 1,6 40,0 
Finland 14,4 11,2 12,6 2,7 1,1 1,8 14,3 
France 10,0 10,6 10,2 1,9 1,1 1,5 14,7 
Spain 6,6 7,2 6,9 1,2 0,9 1,0 14,5 
Switzerland  20,2 20,8 20,3 3,3 1,7 2,4 11,8 
Sweden 17,6 18,8 18,0 3,5 2,1 2,8 15,6 
Estonia 6,4 8,4 7,4 2,9 1,6 2,2 29,7 
Greece 2,9 2,0 2,4 1,2 0,7 0,9 37,5 
Israel 13,0 10,2 11,4 2,8 1,5 2,1 18,4 
RSA 5,5 4,0 4,5 1,7 0,9 1,2 26,7 
Canada 10,4 9,1 9,6 2,4 1,2 1,8 18,8 
USA 16,8 12,6 14,3 2,7 1,2 1,9 13,3 
Japan  0,5 0,7 0,6 0,2 0,2 0,2 33,3 
India 0,2 0,2 0,2 0,1 0,1 0,1 50,0 
Australia 40,5 30,0 34,9 5,8 2,3 4,0 11,5 
Notes:* - according to WHO data, GLOBOCAN 2012 (forecast) 
**-according to the Belarusian сanсer-register for 2012 
 
4. CONCLUSION 
 
Belarus is within the group of countries with a 
relatively low skin melanoma incidence. The 
distinctive features of skin melanoma incidence 
trends in the population of the Republic of 
Belarus are its rapid growth (a 3.3-fold incidence 
increase over 25 years), a high incidence level 
among urban residents, especially in the 
southern part of the country, a large proportion of 
persons affected at the employable age, and a 
higher incidence risk for urban women of young 
and middle age. 
 
Despite the fact that melanoma is diagnosed in 
stages I and II in 85% of the cases, Belarus is 
among the countries with a high 
mortality/incidence ratio (28.1%) and is far 
behind countries with a 2-4 times lower ratio. For 
this reason, one of the burning issues is 
diagnosis of early melanoma. It is worth noting 
that the advances in this area are mainly 
associated with high-quality professional training 
of general practitioners and dermatologists, wide 
use of dermatoscopy in practice enhancing the 
diagnostic accuracy by 20-30% vs naked eye 
clinical examination [8], rather than with 
preventive excision of melanocyte nevi or 
activities within screening programs (no 
screening programs for melanoma or those in 
studies evaluating their efficacy). 
 
A no less important field in the system of 
activities aimed at early melanoma detection is 
systematic education of the population about the 
factors facilitating its development, early 
symptoms of the disease, including mandatory 
informing of solaria customers about the risk of 
malignant skin neoplasm origination. 
 
In the recent years, the technical potential for the 
diagnosis of the extent of melanoma spread 
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considerably increased (positron emission 
tomography, biopsy of sentinel lymph nodes). 
The potential of drug therapies for disseminated 
melanoma has significantly improved. 
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